Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GSK, MTPC to Terminate Copromotion of Adoair
July 12, 2010
- Sawai Considers Entry into Biosimilars Business
July 12, 2010
- Teijin to Create Its Own Marketing Network in China
July 12, 2010
- RA Patients Highly Satisfied with Biologics Treatment: Pfizer
July 12, 2010
- Pfizer Considers Contract Manufacturing Generics in India
July 12, 2010
- 17 New Drugs Recommended for Approval
July 12, 2010
- Astellas Appoints Naoki Okamura as President of OSI Pharm.
July 12, 2010
- PMDA Reduces Review Period to 19.2 M for Ordinary Products
July 12, 2010
- OD Tablet Tester Marketed by Nipro
July 12, 2010
- Effects of New Premium Must Be Verified: New Chuikyo Pricing Subcommittee Chairman
July 12, 2010
- JMHA to Survey Drugs Purchased by Its Member Hospitals Every Year
July 12, 2010
- JPMA Calls on Its Members Not to Refer to Premium When Negotiating Prices
July 12, 2010
- Eisai Licenses Lorcaserin from Arena in the US
July 12, 2010
- Acute-Stage Hospitals Concerned about Increases in Drug Purchase Costs
July 12, 2010
- Pfizer to Strengthen Drug Discovery Alliances in Japan
July 12, 2010
- Council Recommends Approval for 2 Advanced Therapies
July 12, 2010
- Council Holds Hearing on Immunization Programs
July 12, 2010
- Merck Serono Recommences PIII for Stimuvax in NSCLC
July 12, 2010
- Shionogi to Create Its Own Marketing Network in Asia
July 12, 2010
- Yakult Applies for XELOX Regimen for Colon Cancer
July 12, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…